<unk>  is an experimental drug proposed to help treat type 2 diabetes, obesity and non-alcoholic fatty liver disease. It is an analogue of gastric inhibitory polypeptide (GIP), a human hormone which stimulates the release of insulin from the pancreas.<unk>  is a linear polypeptide of 39 amino acids which has been chemically modified by lipidation to improve its uptake into cells and its stability to metabolism. The compound is administered as a weekly subcutaneous injection. It completed phase 3 trials globally in 2021.
Tirzepatide
Plecanatide
Oprelvekin
Vosoritide
Lixisenatide
Abaloparatide
Bulevirtide
Eptifibatide